Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

Yoshiaki Iwasaki, Hiroshi Ikeda, Yasuyuki Araki, Toshiya Osawa, Keiji Kita, Masaharu Ando, Toshinari Shimoe, Kouichi Takaguchi, Noriaki Hashimoto, Toshitsugu Kobatake, Minora Tomita, Mitsuhiko Kawaguchi, Harahiko Kobashi, Kohsaku Sakaguchi, Yasushi Shiratori

Research output: Contribution to journalArticle

127 Citations (Scopus)

Abstract

In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy and safety of combination therapy. We consecutively enrolled 208 patients with naïve chronic hepatitis C. Patients were classified into three groups according to age: younger than 50 years of age (n = 52); 50 to 59 years old (n = 83); and 60 years of age or older (n = 73). Interferon alpha-2b therapy was administered daily for 2 weeks, followed by 3 times per week for 22 weeks, while ribavirin was administered daily. Of the 208 study patients, discontinuation of therapy or dose reduction was required in 116 (56%) and was more frequent in older patient groups: 38%, 48%, and 77% for the

Original languageEnglish
Pages (from-to)54-63
Number of pages10
JournalHepatology
Volume43
Issue number1
DOIs
Publication statusPublished - Jan 2006

    Fingerprint

ASJC Scopus subject areas

  • Hepatology

Cite this

Iwasaki, Y., Ikeda, H., Araki, Y., Osawa, T., Kita, K., Ando, M., Shimoe, T., Takaguchi, K., Hashimoto, N., Kobatake, T., Tomita, M., Kawaguchi, M., Kobashi, H., Sakaguchi, K., & Shiratori, Y. (2006). Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C. Hepatology, 43(1), 54-63. https://doi.org/10.1002/hep.20984